Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Should You Sell?

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down prior to trading on Thursday . The stock had previously closed at $9.61, but opened at $9.19. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.2050, with a volume of 10,709 shares.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Zacks Research cut shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The stock has a market cap of $15.69 billion, a price-to-earnings ratio of 11.53, a PEG ratio of 0.69 and a beta of 0.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.21 and a current ratio of 5.84. The company’s 50 day simple moving average is $10.28 and its 200 day simple moving average is $9.84.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.15 by $0.03. The firm had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. On average, equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.